Independent Advisor Alliance Makes New $791,000 Investment in Indivior PLC $INDV

Independent Advisor Alliance acquired a new stake in Indivior PLC (NASDAQ:INDV) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,034 shares of the company’s stock, valued at approximately $791,000.

Other large investors have also made changes to their positions in the company. CWM LLC purchased a new stake in Indivior during the 3rd quarter worth about $25,000. Quarry LP purchased a new position in Indivior in the 3rd quarter valued at about $26,000. Raymond James Financial Inc. acquired a new stake in shares of Indivior during the 2nd quarter worth about $26,000. Salomon & Ludwin LLC acquired a new stake in shares of Indivior during the 4th quarter worth about $30,000. Finally, Harbor Capital Advisors Inc. grew its holdings in shares of Indivior by 309.9% during the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after buying an additional 781 shares in the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

Insider Buying and Selling at Indivior

In related news, Director Stuart A. Kingsley acquired 940 shares of the stock in a transaction dated Friday, March 6th. The stock was bought at an average cost of $31.86 per share, with a total value of $29,948.40. Following the purchase, the director directly owned 5,582 shares of the company’s stock, valued at approximately $177,842.52. This represents a 20.25% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.74% of the stock is currently owned by company insiders.

Indivior Price Performance

NASDAQ INDV opened at $36.76 on Friday. The company has a market cap of $4.48 billion, a P/E ratio of 18.85 and a beta of 0.90. Indivior PLC has a 12 month low of $11.04 and a 12 month high of $41.00. The company has a 50-day moving average of $32.93 and a 200-day moving average of $33.36.

Indivior (NASDAQ:INDV) last released its earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. The firm had revenue of $317.00 million during the quarter. As a group, equities research analysts anticipate that Indivior PLC will post 3.35 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on INDV. Weiss Ratings downgraded shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, March 16th. Finally, Northland Securities set a $50.00 price target on Indivior in a research note on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $39.33.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.